Table 2 Effects of various protease inhibitors on the 3CLpro and cathepsin L in SARS-CoV-2 replication and entry
|  | EC50 (μM) Virus replication assay | EC50 (μM) Virus entry assay | IC50 (μM) Enzyme assay | ||||
|---|---|---|---|---|---|---|---|
Vero E6 cells | HAE (Primary lung cellsa) | 293 T cells with the replicon | 293 Tcells with ACE2 | 293 Tcells with ACE + TMPRSS2 | 3CLpro | Cath L | |
6ea | 0.15 ± 0.71 |  < 0.5 | 0.01 ± 0.02 | 0.03 ± 0.05 |  > 50 | 0.17 ± 0.06 | 0.03 ± 0.02 |
6ja | 0.8 ± 0.70 |  < 0.5 | 0.03 ± 0.08 | 0.06 ± 0.08 |  > 50 | 0.48 ± 0.08 | 0.05 ± 0.05 |
MDL28170 | N/T | N/T |  > 50 | 0.01 ± 0.02 |  > 50 |  > 50 | 0.01 ± 0.03 |
Z-FL-CHO | N/T | N/T |  > 50 | 0.02 ± 0.03 |  > 50 |  > 50 | 0.01 ± 0.02 |
Nafamostat | N/T | N/T |  > 50 |  > 50 | 0.001 ± 0.02 |  > 50 |  > 50 |